PMID- 31467571
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2019
DP  - 2019
TI  - A Chinese Prescription Chuanxiong Chatiao San for Migraine: A Systematic Review 
      and Meta-Analysis of Randomized Controlled Trials.
PG  - 2301680
LID - 10.1155/2019/2301680 [doi]
LID - 2301680
AB  - BACKGROUNDS: Chuanxiong Chatiao san (CXCT) is a famous Chinese classical 
      prescription. It has a favorable effect in treating migraine. It is reported that 
      CXCT combined with Western conventional medicine (WCM) could increase the 
      therapeutic efficacy on migraine. The purpose of this paper is to systematically 
      assess the clinical efficacy, safety, and some indexes of CXCT for migraine. 
      METHODS: PubMed, Embase Database, China National Knowledge Infrastructure (CNKI), 
      Wanfang Database, the Cochrane Library, and the CBM were searched from January 
      2000 to February 2019. We made a detailed record of outcome measurements. 
      Meta-analysis was performed using RevMan 5.3 software. RESULTS: A total of 3307 
      patients were included in the 37 articles. Meta-analysis showed that CXCT 
      significantly increased the total efficiency rate (TER), compared with Western 
      medicine treatment (WMC) (P < 0.00001). When CXCT is combined with WMC, the 
      result showed that P < 0.00001. CXCT was significantly reduced the adverse events 
      (AEs) compared with WMC (P < 0.00001). The levels of VAS, number of migraine 
      episodes (NE), and time of headache duration (TD) were significantly reduced (P < 
      0.00001). Platelet function and blood rheology level were improved via a 
      significantly decrease in 5-HT and beta-EP (P < 0.00001). Other indicators such as 
      substance P, CGRP high-cut viscosity, low-cut viscosity, plasma viscosity, and 
      fibrinogen were significantly reduced (P < 0.00001). CONCLUSION: Our findings 
      provide evidence that CXCT and CXCT combined with WMC have higher efficacy in the 
      treatment of migraine compared with WCM alone. Methodological quality was 
      generally low, so the conclusion of this paper has some limitations and it has to 
      be carefully evaluated.
FAU - Wang, Yu
AU  - Wang Y
AD  - Department of Pharmaceutics, College of Pharmacy, Shaanxi University of Chinese 
      Medicine, Xianyang, Shaanxi, China.
FAU - Shi, Yajun
AU  - Shi Y
AUID- ORCID: 0000-0003-1178-5504
AD  - Department of Pharmaceutics, College of Pharmacy, Shaanxi University of Chinese 
      Medicine, Xianyang, Shaanxi, China.
AD  - Key Laboratory of Basic and New Drug Research of Traditional Chinese Medicine, 
      Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.
FAU - Zhang, Xiaofei
AU  - Zhang X
AD  - Department of Pharmaceutics, College of Pharmacy, Shaanxi University of Chinese 
      Medicine, Xianyang, Shaanxi, China.
AD  - Key Laboratory of Basic and New Drug Research of Traditional Chinese Medicine, 
      Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.
FAU - Zou, Junbo
AU  - Zou J
AUID- ORCID: 0000-0002-1651-4722
AD  - Department of Pharmaceutics, College of Pharmacy, Shaanxi University of Chinese 
      Medicine, Xianyang, Shaanxi, China.
AD  - Key Laboratory of Basic and New Drug Research of Traditional Chinese Medicine, 
      Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.
FAU - Liang, Yulin
AU  - Liang Y
AD  - Department of Pharmaceutics, College of Pharmacy, Shaanxi University of Chinese 
      Medicine, Xianyang, Shaanxi, China.
FAU - Tai, Jia
AU  - Tai J
AD  - Department of Pharmaceutics, College of Pharmacy, Shaanxi University of Chinese 
      Medicine, Xianyang, Shaanxi, China.
FAU - Wang, Mei
AU  - Wang M
AD  - Department of Pharmaceutics, College of Pharmacy, Shaanxi University of Chinese 
      Medicine, Xianyang, Shaanxi, China.
AD  - Key Laboratory of Basic and New Drug Research of Traditional Chinese Medicine, 
      Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.
FAU - Cui, Chunli
AU  - Cui C
AD  - Department of Pharmaceutics, College of Pharmacy, Shaanxi University of Chinese 
      Medicine, Xianyang, Shaanxi, China.
AD  - Key Laboratory of Basic and New Drug Research of Traditional Chinese Medicine, 
      Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.
FAU - Guo, Dongyan
AU  - Guo D
AD  - Department of Pharmaceutics, College of Pharmacy, Shaanxi University of Chinese 
      Medicine, Xianyang, Shaanxi, China.
AD  - Key Laboratory of Basic and New Drug Research of Traditional Chinese Medicine, 
      Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190731
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC6699287
COIS- We declare that we have no conflicts of interest.
EDAT- 2019/08/31 06:00
MHDA- 2019/08/31 06:01
PMCR- 2019/07/31
CRDT- 2019/08/31 06:00
PHST- 2019/04/12 00:00 [received]
PHST- 2019/06/13 00:00 [accepted]
PHST- 2019/08/31 06:00 [entrez]
PHST- 2019/08/31 06:00 [pubmed]
PHST- 2019/08/31 06:01 [medline]
PHST- 2019/07/31 00:00 [pmc-release]
AID - 10.1155/2019/2301680 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2019 Jul 31;2019:2301680. doi: 
      10.1155/2019/2301680. eCollection 2019.